Is there a need for cholesteryl ester transfer protein inhibition?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 3, 2003, Pages 374-375

  Parini, Paolo ^a   Rude, Lawrence L ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION;

ANIMALS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS;

EID: 0037342988     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000060447.25136.1C     Document Type: Editorial

References (12)

1. Stein EA. An investigative look: selective cholesterol absorption inhibitors-embarking on a new standard of care. Am J Manag Care. 2002;8: S36-S39.
2. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med. 1976;294:293-298.
3. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
4. Rudel LL, Kesaniemi AA. Unraveling the mysteries of high density lipoprotein metabolism. Curr Opin Lipidol. 1999;10:293-294.
5. Quinet E, Tall A, Ramakrishnan R, Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest. 1991;87:1559-1566.
6. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
7. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond). 2002;103:587-594.
8. Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem. 1999;274:1814-1820.
9. Gautier T, Masson D, Jong MC, Duverneuil L, Le Guem N, Deckert V, Pais de Barros JP, Dumont L, Bataille A, Zak Z, Jiang XC, Tall AR, Havekes LM, Lagrost L. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice. J Biol Chem. 2002;277:31354-31363.
10. Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutigue MH, Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem. 2000;275:37504-37509.
11. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem (Tokyo). 1994;116:257-262.
12. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.